| Compound | Description |
|---|
| aspirin | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) |
| dinoprostone | The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. |
| dinoprost | A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. |
| epoprostenol | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). |
| 8,15-leukotriene B4 | RN given refers to cpd without isomeric designation; structure in first source |
| 8-hydroperoxyeicosatetraenoic acid | |
| 5,20-dihydroxy-6,8,11,14-eicosatetraenoic acid | |
| 10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid | structure in 2nd source |
| arachidonic acid | An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. |
| prostaglandin h2 | A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. |
| leukotriene a4 | (2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| leukotriene b4 | The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| leukotriene c4 | The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| thromboxane a2 | An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). |
| 15-keto-5,8,11,13-eicosatetraenoic acid | RN given refers to (E,Z,Z,Z)-isomer; RN for cpd without isomeric designation not available 3/88 |
| 15-keto-13,14-dihydroprostaglandin e2 | RN given refers to (5Z,11alpha)-isomer; structure in first source |
| 15-ketoprostaglandin e2 | metabolite of PGE2; RN given refers to (5Z,11alpha,13E)-isomer |
| 5-hydroxy-6,8,11,14-eicosatetraenoic acid | |
| 5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid | RN given refers to (S-(R*,R*-(E,E,Z,Z)))-isomer |
| 20-carboxyleukotriene b4 | metabolite of leukotriene B4 |
| leukotriene d4 | One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| leukotriene e4 | A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| prostaglandin b2 | RN given refers to (5Z,13E,15S)-isomer |
| 9-deoxy-delta-9-prostaglandin d2 | has potent antineoplastic & weak smooth muscle contracting activities; structure given in first source |
| 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2 | PGD2 metabolite in human plasma |
| Dinoprost | A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. |
| 15-ketoprostaglandin f2alpha | |
| 6-ketoprostaglandin f1 alpha | The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. |
| 11-dehydro-thromboxane b2 | structure given in first source |
| arachidonic acid omega-9 hydroperoxide | |
| lipoxin B4 | structure in first source |
| leukotriene f-4 | formed by transpeptidation of leukotriene E |
| 13,14-dihydro-15-ketoprostaglandin d2 | PGD2 metabolite; RN given refers to (5Z,9alpha)-isomer |
| 15-keto-13,14-dihydroprostaglandin f2alpha | main metabolite of PGF2alpha in plasma after allergen provoked asthma; RN given refers to (5Z,9alpha,11alpha)-isomer; structure |
| thromboxane b2 | A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). |
| 2,3-dinor-thromboxane b2 | |
| 11,12-dihydroxyeicosatrienoic acid | |
| 14,15-dihydroxyeicosatrienoic acid | |
| 12-hydroxy-5,8,10,14-eicosatetraenoic acid | A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51) |
| 20-hydroxy-5,8,11,14-eicosatetraenoic acid | stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer |
| 5,15-dihydroxy-6,8,11,13-eicosatetraenoic acid | RN given refers to (6,13-trans) & (8,11-cis)-isomer |
| 5-oxo-6,8,11,14-eicosatetraenoic acid | RN given is for cpd without isomeric designation; an arachidonate metabolite which stimulates neutrophils to mobilize Ca and promotes PMN degranulation responses |
| 12-keto-5,8,11,13-eicosatetraenoic acid | |
| arachidonic acid 5-hydroperoxide | 5-HPETE is used inconsistently in literature as syn for cpds with various tetraene locants; RN given refers to (6,8,11,14)-isomer; RN in CA Vol 91 Form Index for (E,Z,Z,Z)-isomer: 70968-82-0; RN for (5,8,11,13)-isomer: 71133-12-5; in Merck, arachidonic acid is the (5,8,11,14)-isomer |
| 11-hydroperoxyeicosa-5,8,12,14-tetraenoic acid | |
| 5,6-epoxy-8,11,14-eicosatrienoic acid | RN given refers to cpd without isomeric designation |
| 8,9-epoxyeicosatrienoic acid | RN given refers to cpd without isomeric designation |
| 14,15-epoxy-5,8,11-eicosatrienoic acid | RN given refers to cpd without isomeric designation |
| 8,11,12-trihydroxy-5,9,14-eicosatrienoic acid | structure |
| trioxilin B3 | structure in first source |
| 8-hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid | |
| 15-deoxy-delta(12,14)-prostaglandin j2 | 15-deoxy-PGJ2 is also available; check for double bonds (indicated by delta) at 12 and 14 positions |
| 12-hydroxy-5,8,10-heptadecatrienoic acid | metabolite of arachidonic acid in blood platelet suspension; RN given refers to cpd without isomeric designation |
| 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid | RN given refers to cpd without isomeric designation; (S-(E,Z,Z,Z))-isomer caused dose-dependent constriction of cat coronary arteries; structure in first source |
| 18-hydroxy-5,8,11,14-eicosatetraenoic acid | structure given in first source |
| 15-epi-lipoxin A4 | |
| 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid | major urinary metabolite of PGE in man |
| prostaglandin A2 | RN given refers to (5Z,13E,15S)-isomer |
| eoxin c4 | structure in first source |
| eoxin D4 | |
| 12,20-dihydroxy-5,8,10,14-eicosatetraenoic acid | |
| prostaglandin d2 | The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. |
| eoxin E4 | |